ExpreS2ion Biotech (Q1 Review): Refined development strategy bolstered by strengthened runway - Redeye

Redeye provides a research update following the Q1 report recently published by ExpreS2ion. While the company reported a lower-than-expected cash position due to a negative change in working capital, the report did not contain any major surprises. With further promising interim study data, a refined development plan for ES2B-C001 and a bolstered cash position through the recent rights issue, we believe that ExpreS2ion is a company that investors should keep an eye on. We reiterate our fair value range (SEK1 – SEK10) with a base case valuation of SEK6.

Länk till analysen i sin helhet: https://www.redeye.se/research/1163013/expres2ion-biotech-q1-review-refined-development-strategy-bolstered-by-strengthened-runway?utm_source=finwire&utm_medium=RSS